ABC transporters and cytochromes P450 in the human central nervous system: influence on brain pharmacokinetics and contribution to neurodegenerative disorders

Bibliography

• Guengerich FP, Okazaki O, Seto Y, Radical cation intermediates in N-dealkylation reactions. Xenobiotica 1995;25:689-709
   PubMed Web of Science ®Google Scholar
• Dutheil F, Dauchy S, Diry M, Xenobiotic-metabolizing enzymes and transporters in the normal human brain: regional and cellular mapping as a basis for putative roles in cerebral function. Drug Metab Dispos 2009;37:1528-38
   PubMed Web of Science ®Google Scholar
• Dauchy S, Dutheil F, Weaver RJ, ABC transporters, cytochromes P450 and their main transcription factors: expression at the human blood–brain barrier. J Neurochem 2008;107:1518-28
   PubMed Web of Science ®Google Scholar
• Miksys S, Tyndale RF. Brain drug-metabolizing cytochrome P450 enzymes are active in vivo, demonstrated by mechanism-based enzyme inhibition. Neuropsychopharmacology 2009;34:634-40
   PubMed Web of Science ®Google Scholar
• Hiroi T, Kishimoto W, Chow T, Progesterone oxidation by cytochrome P450 2D isoforms in the brain. Endocrinology 2001;142:3901-8
   PubMed Web of Science ®Google Scholar
• Elbaz A, Levecque C, Clavel J, CYP2D6 polymorphism, pesticide exposure, and Parkinson's disease. Ann Neurol 2004;55:430-4
   PubMed Web of Science ®Google Scholar
• Seliskar M, Rozman D. Mammalian cytochromes P450 – importance of tissue specificity. Biochim Biophys Acta 2007;1770:458-66
   PubMed Web of Science ®Google Scholar
• Michels R, Marzuk PM. Progress in psychiatry (1). N Engl J Med 1993;329:552-60
   PubMed Web of Science ®Google Scholar
• Cohn JA, Alvares AP, Kappas A. On the occurrence of cytochrome P-450 and aryl hydrocarbon hydroxylase activity in rat brain. J Exp Med 1977;145:1607-11
   PubMed Web of Science ®Google Scholar
• Guengerich FP, Mason PS. Immunological comparison of hepatic and extrahepatic cytochromes P-450. Mol Pharmacol 1979;15:154-64
   PubMed Web of Science ®Google Scholar
• Marietta MP, Vesell ES, Hartman RD, Characterization of cytochrome P-450-dependent aminopyrine N-demethylase in rat brain: comparison with hepatic aminopyrine N-demethylation. J Pharmacol Exp Ther 1979;208:271-9
   PubMed Web of Science ®Google Scholar
• Fishman J, Norton BI, Krey L. 2-Hydroxylation of estrogens in the brain participates in the initiation of the preovulatory LH surge in the rat. Biochem Biophys Res Commun 1980;93:471-7
   PubMed Web of Science ®Google Scholar
• Walther B, Ghersi-Egea JF, Minn A, Subcellular distribution of cytochrome P-450 in the brain. Brain Res 1986;375:338-44
   PubMed Web of Science ®Google Scholar
• Ghersi-Egea JF, Walther B, Minn A, Quantitative measurement of cerebral cytochrome P-450 by second derivative spectrophotometry. J Neurosci Methods 1987;20:261-9
   PubMed Web of Science ®Google Scholar
• Bhagwat SV, Boyd MR, Ravindranath V. Rat brain cytochrome P450. Reassessment of monooxygenase activities and cytochrome P450 levels. Drug Metab Dispos 1995;23:651-4
   PubMed Web of Science ®Google Scholar
• Bhagwat SV, Boyd MR, Ravindranath V. Multiple forms of cytochrome P450 and associated monooxygenase activities in human brain mitochondria. Biochem Pharmacol 2000;59:573-82
   PubMed Web of Science ®Google Scholar
• Miksys S, Hoffmann E, Tyndale RF. Regional and cellular induction of nicotine-metabolizing CYP2B1 in rat brain by chronic nicotine treatment. Biochem Pharmacol 2000;59:1501-11
   PubMed Web of Science ®Google Scholar
• Britto MR, Wedlund PJ. Cytochrome P-450 in the brain. Potential evolutionary and therapeutic relevance of localization of drug-metabolizing enzymes. Drug Metab Dispos 1992;20:446-50
   PubMed Web of Science ®Google Scholar
• Lavandera JV, Batlle AM, Buzaleh AM. Metabolization of porphyrinogenic agents in brain: involvement of the phase I drug metabolizing system. A comparative study in liver and kidney. Cell Mol Neurobiol 2007;27:717-29
   PubMed Web of Science ®Google Scholar
• Conroy JL, Fang C, Gu J, Opioids activate brain analgesic circuits through cytochrome P450/epoxygenase signaling. Nat Neurosci 2010;13:284-6
   PubMed Web of Science ®Google Scholar
• Thiebaut F, Tsuruo T, Hamada H, Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues. Proc Natl Acad Sci USA 1987;84:7735-8
   PubMed Web of Science ®Google Scholar
• Miksys SL, Tyndale RF. Drug-metabolizing cytochrome P450s in the brain. J Psychiatry Neurosci 2002;27:406-15
   PubMed Web of Science ®Google Scholar
• Bieche I, Narjoz C, Asselah T, Reverse transcriptase-PCR quantification of mRNA levels from cytochrome (CYP)1, CYP2 and CYP3 families in 22 different human tissues. Pharmacogenet Genomics 2007;17:731-42
   PubMed Web of Science ®Google Scholar
• Nishimura M, Yaguti H, Yoshitsugu H, Tissue distribution of mRNA expression of human cytochrome P450 isoforms assessed by high-sensitivity real-time reverse transcription PCR. Yakugaku Zasshi 2003;123:369-75
   PubMed Web of Science ®Google Scholar
• Howard LA, Miksys S, Hoffmann E, Brain CYP2E1 is induced by nicotine and ethanol in rat and is higher in smokers and alcoholics. Br J Pharmacol 2003;138:1376-86
   PubMed Web of Science ®Google Scholar
• Miksys S, Tyndale RF. The unique regulation of brain cytochrome P450 2 (CYP2) family enzymes by drugs and genetics. Drug Metab Rev 2004;36:313-33
   PubMed Web of Science ®Google Scholar
• el-Bacha RS, Minn A. Drug metabolizing enzymes in cerebrovascular endothelial cells afford a metabolic protection to the brain. Cell Mol Biol (Noisy-le-grand) 1999;45:15-23
   PubMed Web of Science ®Google Scholar
• Granberg L, Ostergren A, Brandt I, CYP1A1 and CYP1B1 in blood–brain interfaces: CYP1A1-dependent bioactivation of 7,12-dimethylbenz(a)anthracene in endothelial cells. Drug Metab Dispos 2003;31:259-65
   PubMed Web of Science ®Google Scholar
• Dean M, Rzhetsky A, Allikmets R. The human ATP-binding cassette (ABC) transporter superfamily. Genome Res 2001;11:1156-66
   PubMed Web of Science ®Google Scholar
• Gottesman MM, Fojo T, Bates SE. Multidrug resistance in cancer: role of ATP-dependent transporters. Nat Rev Cancer 2002;2:48-58
   PubMed Web of Science ®Google Scholar
• Decleves X, Fajac A, Lehmann-Che J, Molecular and functional MDR1-Pgp and MRPs expression in human glioblastoma multiforme cell lines. Int J Cancer 2002;98:173-80
   PubMed Web of Science ®Google Scholar
• Bendayan R, Ronaldson PT, Gingras D, In situ localization of P-glycoprotein (ABCB1) in human and rat brain. J Histochem Cytochem 2006;54:1159-67
   PubMed Web of Science ®Google Scholar
• Juliano RL, Ling V. A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. Biochim Biophys Acta 1976;455:152-62
   PubMed Web of Science ®Google Scholar
• Gazzin S, Strazielle N, Schmitt C, Differential expression of the multidrug resistance-related proteins ABCb1 and ABCc1 between blood–brain interfaces. J Comp Neurol 2008;510:497-507
   PubMed Web of Science ®Google Scholar
• Nies AT, Jedlitschky G, Konig J, Expression and immunolocalization of the multidrug resistance proteins, MRP1-MRP6 (ABCC1-ABCC6), in human brain. Neuroscience 2004;129:349-60
   PubMed Web of Science ®Google Scholar
• Cooray HC, Blackmore CG, Maskell L, Localisation of breast cancer resistance protein in microvessel endothelium of human brain. Neuroreport 2002;13:2059-63
   PubMed Web of Science ®Google Scholar
• Sisodiya SM, Martinian L, Scheffer GL, Vascular colocalization of P-glycoprotein, multidrug-resistance associated protein 1, breast cancer resistance protein and major vault protein in human epileptogenic pathologies. Neuropathol Appl Neurobiol 2006;32:51-63
   PubMed Web of Science ®Google Scholar
• Maliepaard M, Scheffer GL, Faneyte IF, Subcellular localization and distribution of the breast cancer resistance protein transporter in normal human tissues. Cancer Res 2001;61:3458-64
   PubMed Web of Science ®Google Scholar
• Daood M, Tsai C, Ahdab-Barmada M, ABC transporter (P-gp/ABCB1, MRP1/ABCC1, BCRP/ABCG2) expression in the developing human CNS. Neuropediatrics 2008;39:211-18
   PubMed Web of Science ®Google Scholar
• Dombrowski SM, Desai SY, Marroni M, Overexpression of multiple drug resistance genes in endothelial cells from patients with refractory epilepsy. Epilepsia 2001;42:1501-6
   PubMed Web of Science ®Google Scholar
• Zhang W, Mojsilovic-Petrovic J, Andrade MF, The expression and functional characterization of ABCG2 in brain endothelial cells and vessels. FASEB J 2003;17:2085-7
   PubMed Web of Science ®Google Scholar
• Eisenblatter T, Huwel S, Galla HJ. Characterisation of the brain multidrug resistance protein (BMDP/ABCG2/BCRP) expressed at the blood–brain barrier. Brain Res 2003;971:221-31
   PubMed Web of Science ®Google Scholar
• Warren MS, Zerangue N, Woodford K, Comparative gene expression profiles of ABC transporters in brain microvessel endothelial cells and brain in five species including human. Pharmacol Res 2009;59:404-13
   PubMed Web of Science ®Google Scholar
• Huang P, Rannug A, Ahlbom E, Effect of 2,3,7,8-tetrachlorodibenzo-p-dioxin on the expression of cytochrome P450 1A1, the aryl hydrocarbon receptor, and the aryl hydrocarbon receptor nuclear translocator in rat brain and pituitary. Toxicol Appl Pharmacol 2000;169:159-67
   PubMed Web of Science ®Google Scholar
• Iba MM, Storch A, Ghosal A, Constitutive and inducible levels of CYP1A1 and CYP1A2 in rat cerebral cortex and cerebellum. Arch Toxicol 2003;77:547-54
   PubMed Web of Science ®Google Scholar
• Xu C, Li CY, Kong AN. Induction of phase I, II and III drug metabolism/transport by xenobiotics. Arch Pharm Res 2005;28:249-68
   PubMed Web of Science ®Google Scholar
• Nishimura M, Naito S, Yokoi T. Tissue-specific mRNA expression profiles of human nuclear receptor subfamilies. Drug Metab Pharmacokinet 2004;19:135-49
   PubMedGoogle Scholar
• Bensinger SJ, Tontonoz P. Integration of metabolism and inflammation by lipid-activated nuclear receptors. Nature 2008;454:470-7
   PubMed Web of Science ®Google Scholar
• Cordon-Cardo C, O'Brien JP, Casals D, Multidrug-resistance gene (P-glycoprotein) is expressed by endothelial cells at blood–brain barrier sites. Proc Natl Acad Sci USA 1989;86:695-8
   PubMed Web of Science ®Google Scholar
• Akanuma S, Hori S, Ohtsuki S, Expression of nuclear receptor mRNA and liver X receptor-mediated regulation of ABC transporter A1 at rat blood–brain barrier. Neurochem Int 2008;52:669-74
   PubMed Web of Science ®Google Scholar
• Bauer B, Hartz AM, Fricker G, Pregnane X receptor up-regulation of P-glycoprotein expression and transport function at the blood–brain barrier. Mol Pharmacol 2004;66:413-19
   PubMed Web of Science ®Google Scholar
• Dauchy S, Miller F, Couraud PO, Expression and transcriptional regulation of ABC transporters and cytochromes P450 in hCMEC/D3 human cerebral microvascular endothelial cells. Biochem Pharmacol 2009;77:897-909
   PubMed Web of Science ®Google Scholar
• Sasame HA, Ames MM, Nelson SD. Cytochrome P-450 and NADPH cytochrome c reductase in rat brain: formation of catechols and reactive catechol metabolites. Biochem Biophys Res Commun 1977;78:919-26
   PubMed Web of Science ®Google Scholar
• Shafaati M, O'Driscoll R, Bjorkhem I, Transcriptional regulation of cholesterol 24-hydroxylase by histone deacetylase inhibitors. Biochem Biophys Res Commun 2009;378:689-94
   PubMed Web of Science ®Google Scholar
• Baker EK, El-Osta A. Epigenetic regulation of multidrug resistance 1 gene expression: profiling CpG methylation status using bisulphite sequencing. Methods Mol Biol 2010;596:183-98
   PubMedGoogle Scholar
• Tyndale RF, Sunahara R, Inaba T, Neuronal cytochrome P450IID1 (debrisoquine/sparteine-type): potent inhibition of activity by (-)-cocaine and nucleotide sequence identity to human hepatic P450 gene CYP2D6. Mol Pharmacol 1991;40:63-8
   PubMed Web of Science ®Google Scholar
• Tyndale RF, Li Y, Li NY, Characterization of cytochrome P-450 2D1 activity in rat brain: high-affinity kinetics for dextromethorphan. Drug Metab Dispos 1999;27:924-30
   PubMed Web of Science ®Google Scholar
• Zanger UM, Raimundo S, Eichelbaum M. Cytochrome P450 2D6: overview and update on pharmacology, genetics, biochemistry. Naunyn Schmiedebergs Arch Pharmacol 2004;369:23-37
   PubMed Web of Science ®Google Scholar
• Chen ZR, Irvine RJ, Bochner F, Morphine formation from codeine in rat brain: a possible mechanism of codeine analgesia. Life Sci 1990;46:1067-74
   PubMed Web of Science ®Google Scholar
• Eckardt K, Li S, Ammon S, Same incidence of adverse drug events after codeine administration irrespective of the genetically determined differences in morphine formation. Pain 1998;76:27-33
   PubMed Web of Science ®Google Scholar
• Grasmader K, Verwohlt PL, Rietschel M, Impact of polymorphisms of cytochrome-P450 isoenzymes 2C9, 2C19 and 2D6 on plasma concentrations and clinical effects of antidepressants in a naturalistic clinical setting. Eur J Clin Pharmacol 2004;60:329-36
   PubMed Web of Science ®Google Scholar
• Peters EJ, Slager SL, Kraft JB, Pharmacokinetic genes do not influence response or tolerance to citalopram in the STAR*D sample. PLoS One 2008;3:e1872
   PubMed Web of Science ®Google Scholar
• Klein C, Schlossmacher MG. The genetics of Parkinson disease: implications for neurological care. Nat Clin Pract Neurol 2006;2:136-46
   PubMedGoogle Scholar
• Langston JW, Langston EB, Irwin I. MPTP-induced parkinsonism in human and non-human primates – clinical and experimental aspects. Acta Neurol Scand Suppl 1984;100:49-54
   PubMedGoogle Scholar
• Brooks WJ, Jarvis MF, Wagner GC. Astrocytes as a primary locus for the conversion MPTP into MPP+. J Neural Transm 1989;76:1-12
   PubMed Web of Science ®Google Scholar
• Gilham DE, Cairns W, Paine MJ, Metabolism of MPTP by cytochrome P4502D6 and the demonstration of 2D6 mRNA in human foetal and adult brain by in situ hybridization. Xenobiotica 1997;27:111-25
   PubMed Web of Science ®Google Scholar
• Sams C, Mason HJ, Rawbone R. Evidence for the activation of organophosphate pesticides by cytochromes P450 3A4 and 2D6 in human liver microsomes. Toxicol Lett 2000;116:217-21
   PubMed Web of Science ®Google Scholar
• Brown TP, Rumsby PC, Capleton AC, Pesticides and Parkinson's disease – is there a link? Environ Health Perspect 2006;114:156-64
   PubMed Web of Science ®Google Scholar
• Tebourbi O, Driss MR, Sakly M, Metabolism of DDT in different tissues of young rats. J Environ Sci Health B 2006;41:167-76
   PubMed Web of Science ®Google Scholar
• Corrigan FM, Wienburg CL, Shore RF, Organochlorine insecticides in substantia nigra in Parkinson's disease. J Toxicol Environ Health A 2000;59:229-34
   PubMed Web of Science ®Google Scholar
• Kirby ML, Barlow RL, Bloomquist JR. Neurotoxicity of the organochlorine insecticide heptachlor to murine striatal dopaminergic pathways. Toxicol Sci 2001;61:100-6
   PubMed Web of Science ®Google Scholar
• Kitazawa M, Anantharam V, Kanthasamy AG. Dieldrin-induced oxidative stress and neurochemical changes contribute to apoptopic cell death in dopaminergic cells. Free Radic Biol Med 2001;31:1473-85
   PubMed Web of Science ®Google Scholar
• Miller GW, Erickson JD, Perez JT, Immunochemical analysis of vesicular monoamine transporter (VMAT2) protein in Parkinson's disease. Exp Neurol 1999;156:138-48
   PubMed Web of Science ®Google Scholar
• Kanthasamy AG, Kitazawa M, Kanthasamy A, Dieldrin-induced neurotoxicity: relevance to Parkinson's disease pathogenesis. Neurotoxicology 2005;26:701-19
   PubMed Web of Science ®Google Scholar
• Hatcher JM, Richardson JR, Guillot TS, Dieldrin exposure induces oxidative damage in the mouse nigrostriatal dopamine system. Exp Neurol 2007;204:619-30
   PubMed Web of Science ®Google Scholar
• Cascorbi I, Gerloff T, Johne A, Frequency of single nucleotide polymorphisms in the P-glycoprotein drug transporter MDR1 gene in white subjects. Clin Pharmacol Ther 2001;69:169-74
   PubMed Web of Science ®Google Scholar
• Drozdzik M, Bialecka M, Mysliwiec K, Polymorphism in the P-glycoprotein drug transporter MDR1 gene: a possible link between environmental and genetic factors in Parkinson's disease. Pharmacogenetics 2003;13:259-63
   PubMedGoogle Scholar
• Lee CG, Tang K, Cheung YB, MDR1, the blood–brain barrier transporter, is associated with Parkinson's disease in ethnic Chinese. J Med Genet 2004;41:e60
   PubMed Web of Science ®Google Scholar
• Westerlund M, Belin AC, Anvret A, Association of a polymorphism in the ABCB1 gene with Parkinson's disease. Parkinsonism Relat Disord 2009;15:422-4
   PubMed Web of Science ®Google Scholar
• Zschiedrich K, Konig IR, Bruggemann N, MDR1 variants and risk of Parkinson disease. Association with pesticide exposure? J Neurol 2009;256:115-20
   PubMed Web of Science ®Google Scholar
• Dutheil F, Beaune P, Tzourio C, Interaction between ABCB1 and professional exposure to organochlorine insecticides in Parkinson disease. Arch Neurol 2010;67:739-45
   PubMed Web of Science ®Google Scholar
• Bartels AL, Kortekaas R, Bart J, Blood–brain barrier P-glycoprotein function decreases in specific brain regions with aging: a possible role in progressive neurodegeneration. Neurobiol Aging 2009;30:1818-24
   PubMed Web of Science ®Google Scholar
• Selkoe DJ. Alzheimer's disease results from the cerebral accumulation and cytotoxicity of amyloid beta-protein. J Alzheimers Dis 2001;3:75-80
   PubMed Web of Science ®Google Scholar
• Weller RO, Nicoll JA. Cerebral amyloid angiopathy: pathogenesis and effects on the ageing and Alzheimer brain. Neurol Res 2003;25:611-16
   PubMed Web of Science ®Google Scholar
• Shibata M, Yamada S, Kumar SR, Clearance of Alzheimer's amyloid-ss(1-40) peptide from brain by LDL receptor-related protein-1 at the blood–brain barrier. J Clin Invest 2000;106:1489-99
   PubMed Web of Science ®Google Scholar
• Deane R, Du Yan S, Submamaryan RK, RAGE mediates amyloid-beta peptide transport across the blood–brain barrier and accumulation in brain. Nat Med 2003;9:907-13
   PubMed Web of Science ®Google Scholar
• Lam FC, Liu R, Lu P, Beta-amyloid efflux mediated by p-glycoprotein. J Neurochem 2001;76:1121-8
   PubMed Web of Science ®Google Scholar
• Kuhnke D, Jedlitschky G, Grube M, MDR1-P-glycoprotein (ABCB1) mediates transport of Alzheimer's amyloid-beta peptides – implications for the mechanisms of Abeta clearance at the blood–brain barrier. Brain Pathol 2007;17:347-53
   PubMed Web of Science ®Google Scholar
• Cirrito JR, Deane R, Fagan AM, P-glycoprotein deficiency at the blood–brain barrier increases amyloid-beta deposition in an Alzheimer disease mouse model. J Clin Invest 2005;115:3285-90
   PubMed Web of Science ®Google Scholar
• Vogelgesang S, Cascorbi I, Schroeder E, Deposition of Alzheimer's beta-amyloid is inversely correlated with P-glycoprotein expression in the brains of elderly non-demented humans. Pharmacogenetics 2002;12:535-41
   PubMedGoogle Scholar
• Vogelgesang S, Warzok RW, Cascorbi I, The role of P-glycoprotein in cerebral amyloid angiopathy; implications for the early pathogenesis of Alzheimer's disease. Curr Alzheimer Res 2004;1:121-5
   PubMed Web of Science ®Google Scholar
• Xiong H, Callaghan D, Jones A, ABCG2 is upregulated in Alzheimer's brain with cerebral amyloid angiopathy and may act as a gatekeeper at the blood-brain barrier for Abeta(1-40) peptides. J Neurosci 2009;29:5463-75
   PubMed Web of Science ®Google Scholar
• Tai LM, Loughlin AJ, Male DK, P-glycoprotein and breast cancer resistance protein restrict apical-to-basolateral permeability of human brain endothelium to amyloid-beta. J Cereb Blood Flow Metab 2009;29:1079-83
   PubMed Web of Science ®Google Scholar
• Dutheil F, Beaune P, Loriot MA. Xenobiotic metabolizing enzymes in the central nervous system: contribution of cytochrome P450 enzymes in normal and pathological human brain. Biochimie 2008;90:426-36
   PubMed Web of Science ®Google Scholar
• Giacomini KM, Huang SM, Tweedie DJ, Membrane transporters in drug development. Nat Rev Drug Discov 2010;9:215-36
   PubMed Web of Science ®Google Scholar
• Robey RW, To KK, Polgar O, ABCG2: a perspective. Adv Drug Deliv Rev 2009;61:3-13
   PubMed Web of Science ®Google Scholar
• Shimada T, Fujii-Kuriyama Y. Metabolic activation of polycyclic aromatic hydrocarbons to carcinogens by cytochromes P450 1A1 and 1B1. Cancer Sci 2004;95:1-6
   PubMed Web of Science ®Google Scholar
• Vasiliou V, Gonzalez FJ. Role of CYP1B1 in glaucoma. Annu Rev Pharmacol Toxicol 2008;48:333-58
   PubMed Web of Science ®Google Scholar